The production ratios of AICDε51 and Aβ42 by intramembrane proteolysis of βAPP do not always change in parallel

• Published in: Psychogeriatrics Vol. 10; no. 3; pp. 117 - 123
• Main Authors: MORI, Kohji, OKOCHI, Masayasu, TAGAMI, Shinji, NAKAYAMA, Taisuke, YANAGIDA, Kanta, KODAMA, Takashi S., TATSUMI, Shin-ichi, FUJII, Kana, TANIMUKAI, Hitoshi, HASHIMOTO, Ryota, MORIHARA, Takashi, TANAKA, Toshihisa, KUDO, Takashi, FUNAMOTO, Satoru, IHARA, Yasuo, TAKEDA, Masatoshi
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01.09.2010
• Subjects: Aged; AICDε51; Alzheimer Disease - genetics; Alzheimer Disease - physiopathology; Alzheimer's disease; Amyloid beta-Peptides - genetics; Amyloid beta-Peptides - metabolism; Amyloid beta-Protein Precursor - genetics; Amyloid beta-Protein Precursor - metabolism; Amyloid Precursor Protein Secretases - physiology; Cell Membrane - metabolism; Cell-Free System; Cytoplasm - metabolism; DNA Mutational Analysis; Humans; Peptide Fragments - genetics; Peptide Fragments - metabolism; presenilin/γ-secretase; Presenilins - physiology; βAPP; γ-cleavage; ε-cleavage
• ISSN: 1346-3500; 1479-8301
• DOI: 10.1111/j.1479-8301.2010.00330.x

Background:  During intramembrane proteolysis of β‐amyloid protein precursor (βAPP) by presenilin (PS)/γ‐secretase, ε‐cleavages at the membrane‐cytoplasmic border precede γ‐cleavages at the middle of the transmembrane domain. Generation ratios of Aβ42, a critical molecule for Alzheimer's disease (AD) pathogenesis, and the major Aβ40 species might be associated with ε48 and ε49 cleavages, respectively. Medicines to downregulate Aβ42 production have been investigated by many pharmaceutical companies. Therefore, the ε‐cleavages, rather than the γ‐cleavage, might be more effective upstream targets for decreasing the relative generation of Aβ42. Thus, one might evaluate compounds by analyzing the generation ratio of the βAPP intracellular domain (AICD) species (ε‐cleavage‐derived), instead of that of Aβ42. Methods:  Cell‐free γ‐secretase assays were carried out to observe de novo AICD production. Immunoprecipitation/MALDI‐TOF MS analysis was carried out to detect the N‐termini of AICD species. Aβ and AICD species were measured by ELISA and immunoblotting techniques. Results:  Effects on the ε‐cleavage by AD‐associated pathological mutations around the ε‐cleavage sites (i.e., βAPP V642I, L648P and K649N) were analyzed. The V642I and L648P mutations caused an increase in the relative ratio of ε48 cleavage, as expected from previous reports. Cells expressing the K649N mutant, however, underwent a major ε‐cleavage at the ε51 site. These results suggest that ε51, as well as ε48 cleavage, is associated with Aβ42 production. Only AICDε51, though, and not Aβ42 production, dramatically changed with modifications to the cell‐free assay conditions. Interestingly, the increase in the relative ratio of the ε51 cleavage by the K649N mutation was not cancelled by these changes. Conclusion:  Our current data show that the generation ratio of AICDε51 and Aβ42 do not always change in parallel. Thus, to identify compounds that decrease the relative ratio of Aβ42 generation, measurement of the relative level of Aβ42‐related AICD species (i.e., AICDε48 and AICDε51) might not be useful. Further studies to reveal how the ε‐cleavage precision is decided are necessary before it will be possible to develop drugs targeting ε‐cleavage as a means for decreasing Aβ42 production.